PFC Capital Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.24M Buy
6,256
+83
+1% +$97.9K 2.67% 10
2026
Q2
$7.4M Buy
6,173
+90
+1% +$92K 2.85% 9
2026
Q1
$5.59M Buy
6,083
+195
+3% +$198K 2.47% 10
2025
Q4
$6.33M Buy
5,888
+36
+0.6% +$34.4K 2.61% 9
2025
Q3
$4.46M Buy
5,852
+236
+4% +$176K 1.88% 12
2025
Q2
$4.38M Sell
5,616
-632
-10% -$491K 2.03% 12
2025
Q1
$5.16M Sell
6,248
-42
-0.7% -$34.9K 2.6% 11
2024
Q4
$4.86M Buy
6,290
+40
+0.6% +$33.1K 2.35% 12
2024
Q3
$5.54M Buy
6,250
+350
+6% +$315K 2.67% 9
2024
Q2
$5.34M Buy
5,900
+505
+9% +$404K 2.67% 10
2024
Q1
$4.2M Buy
5,395
+65
+1% +$46.3K 2.25% 14
2023
Q4
$3.11M Hold
5,330
– – 1.84% 16

Other funds holding LLY

PFC Capital Group's LLY Position: Q3 2026 in Review

PFC Capital Group increased its Eli Lilly (LLY) stake by 1.3% in Q3 2026, buying an estimated $97.9K and bringing the position to 6,256 shares worth $7.24M. The position accounts for 2.67% of the portfolio, ranked #10.

PFC Capital Group first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $7.4M in Q2 2026. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • PFC Capital Group held 6,256 shares of Eli Lilly worth $7.24M as of Q3 2026.
  • PFC Capital Group bought 83 Eli Lilly shares in Q3 2026, an estimated $97.9K.
  • Eli Lilly made up 2.67% of PFC Capital Group's portfolio in Q3 2026, its #10 holding.
  • PFC Capital Group first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • PFC Capital Group's Eli Lilly position peaked at $7.4M in Q2 2026.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on PFC Capital Group's 13F filing for Q3 2026, filed 6 Nov 2026.